GlassScriptPhysician profile
David A Charles Sokolowski
NPI 1083798870
$4,013.86
in general payments reported to CMS, 2019-2025
34 companies · $463 in 2025
The $463 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $782 · 2020: $567 · 2021: $614 · 2022: $369 · 2023: $361 · 2024: $859 · 2025: $463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,682.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,681.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $797.66 | 2020-2025 | Vraylar, Qulipta, Viberzi |
| Novo Nordisk INC | $498.21 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $341.85 | 2019-2021 | |
| Amgen INC. | $324.72 | 2019-2024 | Evenity, Prolia, Repatha |
| Janssen Pharmaceuticals, INC | $276.21 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $249.98 | 2024 | |
| Abbott Laboratories | $167.26 | 2024-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $147.97 | 2019-2025 | Mounjaro |
| Glaxosmithkline, LLC. | $137.94 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Organon LLC | $102.49 | 2022-2025 | Nexplanon |
| Novartis Pharmaceuticals Corporation | $96.81 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $87.80 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.82 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $73.04 | 2023-2025 | Rexulti |
| Allergan, INC. | $69.70 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.15 | 2023-2025 | Xifaxan |
| Astellas Pharma US INC | $54.29 | 2023-2024 | Veozah, Myrbetriq |
| Pfizer INC. | $52.49 | 2023-2025 | |
| Ironwood Pharmaceuticals, INC | $44.80 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $44.44 | 2020-2024 | Vaxneuvance, Gardasil, Capvaxive |
| Pulmonx Corporation | $43.25 | 2024 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.57 | 2025 | Caplyta |
| Kowa Pharmaceuticals America, INC. | $36.85 | 2020-2023 | Livalo, Seglentis |
| Avanir Pharmaceuticals, INC. | $34.95 | 2020-2021 | |
| Dexcom, INC. | $24.42 | 2021-2022 | |
| Exact Sciences Corporation | $17.14 | 2024 | Cologuard Collection Kit |
| Lundbeck LLC | $14.43 | 2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $14.19 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.70 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $13.32 | 2021 | |
| Sanofi Pasteur INC. | $13.15 | 2020 | |
| Biogen, INC. | $12.63 | 2021 | |
| Genentech USA, INC. | $12.57 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $12.06 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Sokolowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.